就业和职场药物检测市场－全球产业规模、份额、趋势、机会和预测（按类型、产品、模式、药物、最终用途、地区和竞争格局划分），2021-2031年

全球雇主和职场药物检测市场预计将从 2025 年的 63.6 亿美元成长到 2031 年的 84.1 亿美元，复合年增长率为 4.77%。

此市场领域涵盖用于筛检员工非法药物使用和药物滥用的检测服务和诊断产品。市场成长的根本驱动力在于高风险产业严格的政府安全法规，以及企业为最大限度降低与职场和生产力损失相关的责任而做出的努力。这些驱动因素源自于核心营运风险管理和法律合规需求，而非采用新的检测技术。

然而，日益复杂的与大麻相关的法律为市场扩张带来了巨大障碍。州和联邦法律的衝突使得雇主难以法规。这种监管碎片化阻碍了标准化检测通讯协定的实施，并导致对降低后的绩效标准的执行存在不确定性。根据美国卡车运输协会（ATA）的数据，到2024年，大麻将占商业驾驶员阳性药物检测结果的约60%，凸显了企业在不断变化的法律环境下维护安全通讯协定所面临的巨大挑战。

市场驱动因素

严格的政府指令和监管要求，以及对职场安全的迫切需求，是全球雇主和职场药物检测市场的主要驱动因素。在物流和製造业等高风险行业，法律要求雇主实施严格的筛检措施，以预防事故并降低企业责任。持续存在的药物相关安全事故威胁加剧了这种运作上的必要性。根据Quest Diagnostics于2025年9月发布的《2025年药物检测指数》，到2024年，美国工人事故后药物检测呈阳性的比例将达到10.2%，这凸显了在安全事故发生后进行检测以识别风险因素的重要性。这些强制性规定确保了稳定的市场需求基础，使其能够抵御经济波动。

同时，全球非法药物滥用和鸦片类药物成瘾的流行正在推动市场发展，也使得更全面、更频繁的筛检通讯协定变得尤为重要。随着全球药物消费量的增加，员工接触药物的风险也随之上升，迫使各组织实施彻底的检测，以保障员工的生产力和健康。根据联合国毒品犯罪防制署（UNODC）于2024年6月发布的《2024年世界毒品报告》，到2022年，全球非法药物使用者人数将达到2.92亿，比过去十年增长20%。职场的医疗紧急情况进一步凸显了这个问题的严重性。根据美国国家安全委员会（NSC）2025年的数据，2024年，因职场可能发生的阿片类药物过量事件，紧急医疗服务出动次数超过12600次。

市场挑战

日益复杂的与大麻相关的法律为全球雇主和职场药物检测市场的成长带来了重大障碍。儘管越来越多的州已将医用和娱乐用大麻合法化，但联邦法律仍然禁止大麻，这使得雇主面临着错综复杂的相互衝突的合规要求。这种监管碎片化显着增加了在药物影响下工作的法律责任和不确定性，尤其是在非监管职业中。因此，各组织机构变得更加规避风险，缩减筛检程序或完全取消大麻检测以避免诉讼风险。这直接导致检测量减少，并限制了诊断服务的普及。

这种犹豫不决对市场的影响在近期行业数据中显而易见，数据显示，它限制了药物检测的全面普及。根据美国人力资源管理协会（SHRM）统计，截至2024年，只有40%的雇主表示将对受监管和不受监管的职业进行药物检测。这一数字表明，相当一部分企业仍在犹豫是否要实施全面的筛检计画。由于监管方面的混乱，无法建立标准化的检测政策，这有效地限制了市场的目标基本客群，并抑制了收入成长。

市场趋势

在运输部核准和近期对吸食大麻检测需求的推动下，基于实验室的快速口腔液检测正日益普及，并重塑着市场格局。此方法采用全程监控的非侵入式采集方式，降低了尿液检查中常见的检体窜改风险。在安全敏感领域，雇主越来越倾向于采用这种方法来区分过去的大麻史和当前的大麻影响，这在合法化地区至关重要。检测量的显着成长也印证了此操作方式的转变。根据First Advantage于2024年8月发布的《2024年度趋势报告》，过去两年中，基于口腔液的筛检使用量增长了74%，凸显了检测方法结构向着既能确保安全又不惩罚非工作时间行为的转变。

同时，越来越多的机构将Fentanyl纳入其标准药物检测项目，以填补传统检测方法在合成鸦片类药物检测方面的空白。这项扩展至关重要，因为员工在入职前检测中可能呈现阴性，但在工作期间仍可能使用这些物质。检测率的差异凸显了广泛筛检的迫切性。根据Quest Diagnostics于2025年9月发布的《2025年药物检测指数》，随机职场药物检测中Fentanyl的阳性率比入职前检测高出707%。这项数据推动了市场对能够识别传统通讯协定遗漏的强效合成化合物的综合检测项目的需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球雇主与职场药物检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（入职前药物检测/入职后检测）
  • 依产品分类（耗材、设备、快速检测设备、服务）
  • 依检测方式（尿液、毛髮、口腔液、即时检测）
  • 依药物类型（酒精、大麻/毒品、古柯碱、鸦片类药物、安非他命/甲基安非他命、LSD、其他）
  • 依最终用途（IT/金融、製造业、运输业、建筑业、零售/旅馆业、医疗保健业、教育业、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美雇主和职场药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲雇主和职场药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区雇主和职场药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲雇主及职场药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲雇主和职场药物检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球雇主与职场药物检测市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• First Advantage Corporation
• Laboratory Corporation of America Holdings
• Dragerwerk AG & Co. KGaA
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories, Inc.
• Clinical Reference Laboratory Inc.
• Quest Diagnostics Inc.
• DISA Global Solutions Inc.
• HireRight, LLC
• OraSure Technologies Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Employer And Workplace Drug Testing Market is projected to expand from a valuation of USD 6.36 Billion in 2025 to USD 8.41 Billion by 2031, reflecting a compound annual growth rate of 4.77%. This market sector encompasses the laboratory services and diagnostic products used by organizations to screen their workforce for illicit substance use or medication misuse. The market's growth is fundamentally anchored by strict government safety mandates in high-risk industries and a corporate commitment to minimizing liabilities associated with workplace accidents and productivity losses. These drivers arise from core operational risk management and legal compliance necessities rather than the mere adoption of new collection technologies.

However, the expansion of the market faces a significant hurdle due to the growing complexity of cannabis legislation, which creates compliance difficulties for employers dealing with contradictory state and federal laws. This regulatory fragmentation hampers the implementation of standardized testing protocols and generates uncertainty regarding the enforcement of impairment standards. Data from the American Trucking Associations indicates that in 2024, marijuana was responsible for nearly 60% of all positive drug tests among commercial drivers, underscoring the severe challenges organizations encounter in maintaining safety protocols within this shifting legal environment.

Market Driver

Strict government mandates and regulatory compliance, alongside the urgent need for workplace safety, serve as the primary catalysts for the Global Employer And Workplace Drug Testing Market. In high-stakes sectors such as logistics and manufacturing, employers are legally obligated to enforce rigorous screening measures to prevent accidents and reduce corporate liability. This operational necessity is intensifying as safety incidents involving impairment remain a persistent threat. According to the '2025 Drug Testing Index' by Quest Diagnostics, released in September 2025, the positivity rate for post-accident drug tests in the U.S. workforce hit 10.2% in 2024, highlighting the crucial role of testing in identifying hazards following safety failures. These mandates ensure a consistent baseline of market demand that remains resilient against economic fluctuations.

Simultaneously, the market is propelled by the rising global prevalence of illicit substance use and opioid addiction, which necessitates more comprehensive and frequent screening protocols. As drug consumption increases worldwide, the risk of employee impairment rises, compelling organizations to adopt thorough testing to safeguard productivity and workforce health. The UNODC's 'World Drug Report 2024', published in June 2024, reveals that the number of people using illicit drugs globally climbed to 292 million in 2022, a 20% increase over the previous decade. The severity of this issue is further illustrated by workplace medical emergencies; according to the National Safety Council in 2025, Emergency Medical Services were activated over 12,600 times in 2024 to respond to potential opioid overdoses in workplace settings.

Market Challenge

The escalating complexity of cannabis legislation presents a formidable barrier to the growth of the Global Employer and Workplace Drug Testing Market. With states legalizing marijuana for medical and recreational use while it remains federally illegal, employers face a conflicting maze of compliance requirements. This regulatory fragmentation creates significant legal liability and uncertainty regarding impairment enforcement, particularly for non-regulated roles. Consequently, organizations are becoming risk-averse, often choosing to scale back their screening protocols or eliminate marijuana testing entirely to avoid potential lawsuits, which directly reduces test volumes and limits the adoption of diagnostic services.

The market impact of this hesitancy is evident in recent industry data showing restricted comprehensive adoption. According to the Society for Human Resource Management, in 2024, only 40% of employers reported conducting drug testing for both regulated and non-regulated roles. This figure indicates that a substantial segment of the corporate landscape is refraining from implementing full-scale screening programs. The inability to establish standardized testing policies due to legislative confusion effectively limits the market's addressable customer base and hampers revenue growth.

Market Trends

The market is being reshaped by the widespread adoption of lab-based and rapid oral fluid testing, driven by Department of Transportation approval and the necessity to detect recent use. This method mitigates the risk of specimen adulteration common in urine testing by utilizing fully observed, non-invasive collections. Employers in safety-sensitive sectors are increasingly favoring this modality to distinguish active impairment from historical cannabis use, a capability that is crucial in legalized jurisdictions. This operational shift is quantified by significant volume growth; according to First Advantage's '2024 Annual Trends Report' from August 2024, the utilization of oral fluid-based screens grew by 74% over the preceding two years, highlighting a structural pivot toward testing methods that enforce safety without penalizing off-duty conduct.

Concurrently, organizations are expanding standard drug panels to include fentanyl, addressing the gap where legacy screens fail to detect synthetic opioids. This expansion is critical as employees may pass pre-employment checks while using these substances on the job. The urgency for broader screening is highlighted by disparities in detection rates; according to Quest Diagnostics' '2025 Drug Testing Index' from September 2025, the positivity rate for fentanyl in random workforce drug tests was 707% higher than in pre-employment tests. This statistic drives the market demand for comprehensive panels capable of identifying potent synthetic compounds missed by traditional protocols.

Key Market Players

• First Advantage Corporation
• Laboratory Corporation of America Holdings
• Dragerwerk AG & Co. KGaA
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories, Inc.
• Clinical Reference Laboratory Inc.
• Quest Diagnostics Inc.
• DISA Global Solutions Inc.
• HireRight, LLC
• OraSure Technologies Inc

Report Scope

In this report, the Global Employer And Workplace Drug Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Employer And Workplace Drug Testing Market, By Type

• Pre-employment Drug Screens and Post-employment

Employer And Workplace Drug Testing Market, By Product

• Consumables
• Instruments
• Rapid Testing Devices
• and Services

Employer And Workplace Drug Testing Market, By Mode

• Urine
• Hair
• Oral Fluid
• and Instant Testing

Employer And Workplace Drug Testing Market, By Drug

• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• and Others

Employer And Workplace Drug Testing Market, By End Use

• IT/Finance
• Manufacturing
• Transportation
• Construction
• Retail & Hospitality
• Healthcare
• Education
• Others

Employer And Workplace Drug Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Employer And Workplace Drug Testing Market.

Available Customizations:

Global Employer And Workplace Drug Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Employer And Workplace Drug Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Pre-employment Drug Screens and Post-employment)
  • 5.2.2. By Product (Consumables, Instruments, Rapid Testing Devices, and Services)
  • 5.2.3. By Mode (Urine, Hair, Oral Fluid, and Instant Testing)
  • 5.2.4. By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, and Others)
  • 5.2.5. By End Use (IT/Finance, Manufacturing, Transportation, Construction, Retail & Hospitality, Healthcare, Education, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Employer And Workplace Drug Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Mode
  • 6.2.4. By Drug
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Employer And Workplace Drug Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Mode
      • 6.3.1.2.4. By Drug
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada Employer And Workplace Drug Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Mode
      • 6.3.2.2.4. By Drug
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico Employer And Workplace Drug Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Mode
      • 6.3.3.2.4. By Drug
      • 6.3.3.2.5. By End Use

7. Europe Employer And Workplace Drug Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Mode
  • 7.2.4. By Drug
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Employer And Workplace Drug Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Mode
      • 7.3.1.2.4. By Drug
      • 7.3.1.2.5. By End Use
  • 7.3.2. France Employer And Workplace Drug Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Mode
      • 7.3.2.2.4. By Drug
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom Employer And Workplace Drug Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Mode
      • 7.3.3.2.4. By Drug
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy Employer And Workplace Drug Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Mode
      • 7.3.4.2.4. By Drug
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain Employer And Workplace Drug Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Mode
      • 7.3.5.2.4. By Drug
      • 7.3.5.2.5. By End Use

8. Asia Pacific Employer And Workplace Drug Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Mode
  • 8.2.4. By Drug
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Employer And Workplace Drug Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Mode
      • 8.3.1.2.4. By Drug
      • 8.3.1.2.5. By End Use
  • 8.3.2. India Employer And Workplace Drug Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Mode
      • 8.3.2.2.4. By Drug
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan Employer And Workplace Drug Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Mode
      • 8.3.3.2.4. By Drug
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea Employer And Workplace Drug Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Mode
      • 8.3.4.2.4. By Drug
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia Employer And Workplace Drug Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Mode
      • 8.3.5.2.4. By Drug
      • 8.3.5.2.5. By End Use

9. Middle East & Africa Employer And Workplace Drug Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Mode
  • 9.2.4. By Drug
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Employer And Workplace Drug Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Mode
      • 9.3.1.2.4. By Drug
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE Employer And Workplace Drug Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Mode
      • 9.3.2.2.4. By Drug
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa Employer And Workplace Drug Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Mode
      • 9.3.3.2.4. By Drug
      • 9.3.3.2.5. By End Use

10. South America Employer And Workplace Drug Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Mode
  • 10.2.4. By Drug
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Employer And Workplace Drug Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Mode
      • 10.3.1.2.4. By Drug
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia Employer And Workplace Drug Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Mode
      • 10.3.2.2.4. By Drug
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina Employer And Workplace Drug Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Mode
      • 10.3.3.2.4. By Drug
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Employer And Workplace Drug Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. First Advantage Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Laboratory Corporation of America Holdings
• 15.3. Dragerwerk AG & Co. KGaA
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Abbott Laboratories, Inc.
• 15.6. Clinical Reference Laboratory Inc.
• 15.7. Quest Diagnostics Inc.
• 15.8. DISA Global Solutions Inc.
• 15.9. HireRight, LLC
• 15.10. OraSure Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer